Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

MLA

Arne Kolstad, et al. Nordic MCL3 Study: Y-90-Ibritumomab-Tiuxetan Added to BEAM/C in Non-CR Patients before Transplant in Mantle Cell Lymphoma. Jan. 2014. EBSCOhost, https://doi.org/10.1182/blood-2013-12-541953.

APA

Arne Kolstad, Lone Bredo Pedersen, Unn-Merete Fagerli, Christer Sundström, Kirsten Grønbæk, Elisabeth Ralfkiaer, Erkki Elonen, Anne Kristine Lehmann, Kamelia Kostova-Aherdan, Eva Kimby, Jan Delabie, Trond Velde Bogsrud, Peter de Nully Brown, Annika Loft, Christian H. Geisler, Jukka Schildt, Mats Ehinger, Per Boye Hansen, Henrik Frederiksen, … Herman Nilsson-Ehle. (2014). Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. https://doi.org/10.1182/blood-2013-12-541953

Chicago

Arne Kolstad, Lone Bredo Pedersen, Unn-Merete Fagerli, Christer Sundström, Kirsten Grønbæk, Elisabeth Ralfkiaer, Erkki Elonen, et al. 2014. “Nordic MCL3 Study: Y-90-Ibritumomab-Tiuxetan Added to BEAM/C in Non-CR Patients before Transplant in Mantle Cell Lymphoma,” January. doi:10.1182/blood-2013-12-541953.